Veracyte, Inc. (VCYT) stock
Close on Nov 13, 2026Market cap $1.96BP/E 15.8Yield –
Veracyte, Inc. grew revenue 17.5% to $581.78M over the twelve months to Sep 30, 2026. Operating income rose 301.5% to $99.39M, moving the operating margin from 5.0% to 17.1%. Free cash flow was $161.95M, up 64.9% from a year earlier. At the latest close the market valued the company at $1.96B, 15.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.96B
- P/E ratio
- 15.8
- Price to sales
- 3.36
- Price to book
- 1.36
- Dividend yield
- –
- Free cash flow yield
- 8.28%
Fundamentals
- Revenue
- $581.78M
- Net income
- $126.85M
- EPS, diluted
- $1.54
- Free cash flow
- $161.95M
- Book value per share
- $17.31
- Diluted shares
- 83M
Trading
- Next earnings
- Feb 24, 2027 (estimated, during market hours)
- Previous close
- $24.63
- Open
- $24.49
- Day's range
- $23.45 – $24.65
- Volume
- 2,029,483
- Average volume (20 days)
- 2,705,746
- Index membership
- S&P SmallCap 600 (since Aug 2025), Russell 2000, Russell 3000
- Beta (5 years)
- 1.78
- 52-week range
- $21.91 – $60.91
- RSI (14 days)
- 28.1
- Volatility (1 year)
- 81.2%
- Relative volume
- 1.24×
- WACC
- 14.0%
On 1 of our idea list: Undervalued and financially sound
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | VCYT | S&P 500 | Difference | VCYT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -43.6% | -3.0% | −40.5 pts | ||
| 3 months | -42.9% | -2.8% | −40.1 pts | ||
| Year to date | -42.2% | +11.5% | −53.7 pts | ||
| 1 year | -39.0% | +13.5% | −52.4 pts | ||
| 3 years | +6.0% | +77.7% | −71.7 pts | +2.0% | +21.1% |
| 5 years | -49.5% | +72.6% | −122.1 pts | -12.8% | +11.5% |
| 10 years | +247.6% | +308.2% | −60.6 pts | +13.3% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Veracyte filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Veracyte
Services-Medical Laboratories
Veracyte is a molecular diagnostics company that develops and performs clinical genomic tests to assist in diagnosing and treating various forms of cancer. Its primary commercial offerings include Decipher tests for prostate and bladder cancers, the Afirma classifier for thyroid nodules, and the Prosigna assay for breast cancer. The business operates through laboratory developed tests analyzed in centralized facilities as well as distributed in vitro diagnostic test kits. Its customers include physicians, endocrinologists, oncologists, hospitals, independent laboratories, and biopharmaceutical partners.
Company profile, executives and historyVeracyte stock: common questions
What is Veracyte's stock price?
VCYT closed at $24.33 on Nov 13, 2026, down 1.22% on the day. Over the past 52 weeks it traded between $21.91 and $60.91.
What is Veracyte's market cap?
Veracyte was worth $1.96B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is VCYT's P/E ratio?
VCYT trades at 15.8 times earnings, based on diluted earnings per share of $1.54 over the twelve months to Sep 30, 2026.
How much revenue does Veracyte make?
Veracyte reported revenue of $581.78M for the twelve months to Sep 30, 2026, up 17.5% from a year earlier.
Does Veracyte pay a dividend?
No. Veracyte has not paid a cash dividend over the last twelve months.
When does Veracyte report earnings next?
Veracyte is expected to report Q4 FY2026 results on Feb 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has VCYT stock performed over the past year?
Including dividends, VCYT returned -39.0% over the past year, against +13.5% for the S&P 500.
How many VCYT shares are sold short?
10M shares were sold short at the latest FINRA report, 12.10% of the float, or 8.2 days of average trading volume.
Who are Veracyte's competitors?
Companies most similar to Veracyte by business, industry and size include BNR, CSTL, CDNA, GH, FLGT.
See a number that looks wrong?